Market closedNon-fractional

Sutro Biopharma/STRO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Sutro Biopharma

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Ticker

STRO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South San Francisco, United States

Employees

300

Sutro Biopharma Metrics

BasicAdvanced
$239M
Market cap
-
P/E ratio
-$1.89
EPS
1.09
Beta
-
Dividend rate
$239M
1.09
4.46
4.333
21.828
28.636
-5.04%
-17.01%
-81.12%
1.153
1.86
1.86
-1.491
106.66%
-21.91%
45.29%
18.99%

What the Analysts think about Sutro Biopharma

Analyst Ratings

Majority rating from 11 analysts.
Buy

Sutro Biopharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-447.69% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$13M
-88.57%
Net income
-$58M
-287.74%
Profit margin
-447.69%
-1,742.30%

Sutro Biopharma Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.04%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.64
-$0.81
$0.52
-$0.95
-
Expected
-$0.73
-$0.74
-$0.82
-$0.92
-$0.79
Surprise
-12.63%
10.05%
-163.16%
3.04%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Sutro Biopharma stock?

Sutro Biopharma (STRO) has a market cap of $239M as of July 06, 2024.

What is the P/E ratio for Sutro Biopharma stock?

The price to earnings (P/E) ratio for Sutro Biopharma (STRO) stock is 0 as of July 06, 2024.

Does Sutro Biopharma stock pay dividends?

No, Sutro Biopharma (STRO) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Sutro Biopharma dividend payment date?

Sutro Biopharma (STRO) stock does not pay dividends to its shareholders.

What is the beta indicator for Sutro Biopharma?

Sutro Biopharma (STRO) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Sutro Biopharma stock

Buy or sell Sutro Biopharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing